D
Pharming Group N.V.
PHGUF
$0.90
$0.1113.92%
D
Sell
1/6/2025Upgraded
Pharming Group N.V. (PHGUF) was upgraded to D- from E+ on 1/6/2025 due to a substantial increase in the growth index, solvency index and volatility index.
Pharming Group N.V. (PHGUF) was upgraded to D- from E+ on 1/6/2025 due to a substantial increase in the growth index, solvency index and volatility index.
E
Sell
8/5/2024Downgrade
Pharming Group N.V. (PHGUF) was downgraded to E+ from D on 8/5/2024 due to a significant decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 3.28 to 2.65, and total capital declined 12.13% from $390.33M to $342.96M.
Pharming Group N.V. (PHGUF) was downgraded to E+ from D on 8/5/2024 due to a significant decline in the efficiency index, volatility index and solvency index. The quick ratio declined from 3.28 to 2.65, and total capital declined 12.13% from $390.33M to $342.96M.
D
Sell
4/11/2024Downgrade
Pharming Group N.V. (PHGUF) was downgraded to D from D+ on 4/11/2024 due to a significant decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.0015 to -$0.0046, and net income declined 336.77% from $1.32M to -$3.12M.
Pharming Group N.V. (PHGUF) was downgraded to D from D+ on 4/11/2024 due to a significant decline in the growth index, total return index and efficiency index. Earnings per share declined from $0.0015 to -$0.0046, and net income declined 336.77% from $1.32M to -$3.12M.
D
Sell
12/13/2023Downgrade
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 12/13/2023 due to a decline in the volatility index, total return index and growth index.
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 12/13/2023 due to a decline in the volatility index, total return index and growth index.
C
Hold
10/30/2023Upgraded
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 10/30/2023 due to an increase in the growth index, efficiency index and valuation index.
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 10/30/2023 due to an increase in the growth index, efficiency index and valuation index.
D
Sell
10/13/2023Downgrade
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 10/13/2023 due to a decline in the total return index.
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 10/13/2023 due to a decline in the total return index.
C
Hold
9/13/2023Upgraded
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 9/13/2023 due to a major increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0236 to $0.0015, EBIT increased 12.54% from -$18.04M to -$15.78M, and total revenue increased 0.51% from $54.62M to $54.9M.
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 9/13/2023 due to a major increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.0236 to $0.0015, EBIT increased 12.54% from -$18.04M to -$15.78M, and total revenue increased 0.51% from $54.62M to $54.9M.
D
Sell
4/6/2023Downgrade
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 4/6/2023 due to a large decline in the efficiency index, valuation index and solvency index. Net income declined 192.94% from $15.74M to -$14.63M, the quick ratio declined from 4.53 to 3.9, and debt to equity increased from 0.66 to 0.67.
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 4/6/2023 due to a large decline in the efficiency index, valuation index and solvency index. Net income declined 192.94% from $15.74M to -$14.63M, the quick ratio declined from 4.53 to 3.9, and debt to equity increased from 0.66 to 0.67.
C
Hold
9/6/2022Upgraded
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 9/6/2022 due to an increase in the volatility index and total return index.
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 9/6/2022 due to an increase in the volatility index and total return index.
D
Sell
4/18/2022Downgrade
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 4/18/2022 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 52.54% from $5.84M to $2.77M, earnings per share declined from $0.007 to $0.0044, and EBIT declined 13.16% from $10.88M to $9.44M.
Pharming Group N.V. (PHGUF) was downgraded to D+ from C- on 4/18/2022 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 52.54% from $5.84M to $2.77M, earnings per share declined from $0.007 to $0.0044, and EBIT declined 13.16% from $10.88M to $9.44M.
C
Hold
3/31/2022Upgraded
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 3/31/2022 due to an increase in the volatility index.
Pharming Group N.V. (PHGUF) was upgraded to C- from D+ on 3/31/2022 due to an increase in the volatility index.
D
Sell
3/21/2022Upgraded
Pharming Group N.V. (PHGUF) was upgraded to D+ from E+ on 3/21/2022 due to an increase in the valuation index.
Pharming Group N.V. (PHGUF) was upgraded to D+ from E+ on 3/21/2022 due to an increase in the valuation index.
E
Sell
5/3/2021Upgraded
Pharming Group N.V. (PHGUF) was upgraded to E+ from E- on 5/3/2021 due to an increase in the valuation index, total return index and volatility index.
Pharming Group N.V. (PHGUF) was upgraded to E+ from E- on 5/3/2021 due to an increase in the valuation index, total return index and volatility index.
E
Sell
4/21/2021Downgrade
Pharming Group N.V. (PHGUF) was downgraded to E- from E on 4/21/2021 due to a large decline in the volatility index and valuation index.
Pharming Group N.V. (PHGUF) was downgraded to E- from E on 4/21/2021 due to a large decline in the volatility index and valuation index.
E
Sell
2/22/2021None
Pharming Group N.V. (PHGUF) was downgraded to E from U on 02/22/2021.
Pharming Group N.V. (PHGUF) was downgraded to E from U on 02/22/2021.
OTC PK
03/13/2025 11:58AM Eastern
Quotes delayed
